Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: November 2015

23 - Management of cancer of the testis

Related content

Powered by UNSILO
Bokemeyer, C. and Schmoll, H. J. (1995). Treatment of testicular cancer and the development of secondary malignancies. J. Clin. Oncol., 13, 283–292.
Cullen, M. H., Stenning, S. P., Parkinson, M. C., et al. (1996). Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol., 14, 1106–1113.
De Wit, M., Hartmann, M., Brenner, W., et al. (2006). [18F]-FDG-PET in germ cell tumors following chemotherapy: results of the German multicenter trial. J. Clin. Oncol., 24(18 Suppl.), 4521.
Fossa, S. D., Horwich, A., Russell, J. M., et al. (1999). Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J. Clin. Oncol., 17, 1146.
Grimison, P. S, Stockler, M. R., Chatfield, M., et al. (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Ann. Oncol., 25, 143–148.
Harland, S. J., Cook, P. A., Fossa, S. D., et al. (1998). Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J. Urol., 160, 1353–1357.
Hendry, W. F., A'Hern, R. P., Hetherington, J. W., et al. (1993). Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br. J. Urol., 71, 208–213.
Horwich, A., Oliver, R. T., Wilkinson, P. M., et al. (2000). A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br. J. Cancer, 83, 1623–1629.
Huddart, R., O'Doherty, M., Padhani, A., et al. (2006). A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. J. Clin. Oncol., 24(18 Suppl.), 4520.
IGCCCG. (1997). International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol., 15, 594–603.
Lampe, H., Horwich, A., Norman, A., et al. (1997). Fertility after chemotherapy for testicular germ cell cancers. J. Clin. Oncol., 15, 239–245.
Lorch, A., Kollmannsberger, C., Hartmann, J. T., et al. (2007). Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J. Clin. Oncol., 25, 2778–2784.
Lorch, A., Bascoul-Mollevi, C., Kramar, A., et al. (2011). Conventional dose versus high dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumours, an international database. J. Clin. Oncol., 29, 2178–2184.
Mead, G. M., Rustin, G. J., Stenning, S. P., et al. (2006). Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis. J. Clin. Oncol., 24 (18 Suppl.), 4519.
Oliver, R. T., Mason, M., Mead, G. M., et al. (2005). Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet, 366, 293–300.
O'Sullivan, J. M., Huddart, R. A., Norman, A. R., et al. (2003). Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol., 14, 91–96.
Parker, K., Smith, C. and Barber, J. (2011). Case series of 16 patients with stage II seminoma treated with sequential carboplatin AUC7 then para-aortic radiotherapy. Clin. Oncol. (R. Coll. Radiol.), 23, 70.
Patterson, H., Norman, A. R., Mitra, S. S., et al. (2001). Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother. Oncol., 59, 5–11.
Pico, J. L., Rosti, G., Kramar, A., et al. (2005). A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumoursAnn. Oncol., 16, 1152–1159.
Shahidi, M., Norman, A. R., Dearnaley, D. P., et al. (2002). Late recurrences in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer, 95, 520–530.
Tandstad, T., Cavallin-Stahl, E., Dahl, O., et al. (2013). One course of adjuvant BEP in clinical stage I, nonseminoma: mature and expanded results from the SWENOTECA group. J. Clin. Oncol., 31 (Suppl.; abstr. 4553).
Tandstad, T., Cavallin-Stahl, E., Dahl, O., et al. (2014). Management of clinical stage I seminomatous testicular cancer: a report from SWENOTECA.J. Clin. Oncol., 32 (Suppl.; abstr. 4508).
Williams, S. D., Birch, R., Einhorn, L. H., et al. (1987). Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med., 316, 1435–1440.